Bivalirudin
General Information
Bivalirudin Impurities
Daicel Pharma synthesizes high-quality Bivalirudin impurity, 12-20-Bivalirudin, which helps in quality, stability, and biological safety analysis of the API, Bivalirudin. We offer custom synthesis of Bivalirudin impurities and can supply globally.
Bivalirudin
Bivalirudin [CAS: 128270-60-0] is a short, synthetic 20 amino acid peptide used in drugs that act as potent and highly specific thrombin inhibitors. It acts as an anticoagulant to treat heparin-induced thrombocytopenia and to prevent thrombosis during percutaneous coronary intervention.
Bivalirudin: Use and Commercial Availability
Bivalirudin is a direct thrombin inhibitor (DTI) and used for acute myocardial infarction, heparin-induced thrombocytopenia (HIT), percutaneous coronary intervention (PCI), and unstable angina.
Bivalirudin is available under the brand names, Angiomax and Angiomax RTU (injectable for IV use). It is also present as Bivalirudin Trifluoroacetate (Bivalirudin TFA salt).
Bivalirudin Structure and Mechanism of Action
The chemical formula of Bivalirudin is C98H138N24O33, and its molecular weight is 2180.3 g/mol.
Bivalirudin inhibits thrombin by binding to the catalytic site and the anion-binding exosite of circulating and clot-bound thrombin. Thrombin cleaves fibrinogen into fibrin monomers and activates Factor XIII to Factor XIIIa and stabilizes the thrombus. In addition, it activates Factors V and VIII, further promoting thrombin generation and platelet activation.
Bivalirudin Impurities and Synthesis
During the manufacture of Bivalirudin and its purification process1 different types of Bivalirudin impurities develop like deamidated Bivalirudin, oxidized Bivalirudin, truncated Bivalirudin, and diastereomers. Also, impurities form due to residual solvents, reagents, by-products, and more. 12-20-Bivalirudin is a truncated form of Bivalirudin impurity, which needs identification and quantification to ensure that the final product is safe and meets the required quality standards.
At Daicel, we provide a Certificate of Analysis (CoA) from a cGMP-compliant analytical facility for Bivalirudin impurity standard, 12-20-Bivalirudin, with complete characterization data including 1H NMR, 13C NMR, IR, MASS, and HPLC purity. We also provide 13C-DEPT and CHN on request. In addition, we provide a complete characterization report upon delivery. Daicel offers highly pure isotope-labeled standards of Bivalirudin in bioanalytical research and BA/BE studies with isotope data in CoA.
References
FAQ's
References
- Tovi, A., Eidelman, C., Shushan, S., Hagi, A., Ivchenko, A., Butilca, G.M., Bar-Oz, L., Gadi, T. and Zaovi, G., TEVA Pharmaceuticals, USA, “Process for the production of Bivaluridin” US patent application US20130196916A1, August 4, 2013
- Sadekar, Shivaraj D.; Chilkawar, Ramchandra N.; Patil, S. M.; Saboji, J. K.; Nanjwade, Basavaraj K, “Development and validation of a spectrophotometric method for estimation of Bivalirudin” Austin Journal of Analytical and Pharmaceutical Chemistry, Volume: 1, Issue: 5, Pages: id1024,2014
- Scientific discussion in EU on Bivalirudin
Frequently Asked Questions
How to synthesize Bivalirudin impurities?
The synthesis of Bivalirudin impurities involves identifying their chemical structure, developing a synthesis strategy, and purifying the final product. The process uses specialized equipment and techniques, including high-pressure reaction vessels, vacuum distillation, and chromatography. The purity of the final product is analyzed using analytical techniques such as HPLC and MS2.
What are the temperature conditions required to store Bivalirudin impurities?
Bivalirudin impurities are stored at a controlled room temperature between 20°C to 25°C (68°F to 77°F). They should not be exposed to temperatures above 30°C (86°F). In addition, any peptide-related impurities should be stored at -20±5 ⁰C for long-term storage.
How are Bivalirudin impurities identified?
Bivalirudin impurities are identified when purifying synthetic peptides by reverse phase preparative HPLC3.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.
